Trials Sponsors Conditions Drugs Pricing

Conditions

HIV

Keywords

HIVOpportunistic DiseasesTuberculosisAIDSSexually Transmitted InfectionNatural History

Outcome Measures

Primary Outcomes (2)

Description of disease course
Description of the course of HIV disease in the study population as a whole or by subgroup.
Months 1,3,6,12,18,24,30,36
Characteritics of study population
Description of major social/demographic, clinical, immunologic, and virologic characteristics of HIV disease in the study population at baseline.
Baseline

Secondary Outcomes (1)

ARV Genotypic Resistance Mutations
1 year

Study Arms (1)

1

HIV Positive

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

cohort of individuals currently receiving or initiating care for HIV infection in Margibi and Montserrado Counties, Liberia.

You may qualify if:

Individuals of any age and gender must meet all of the following criteria to be eligible for study participation:

Sponsors & Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
NIHlead

Study Sites (4)

C.H. Rennie Hospital

Kakata, Liberia

John F. Kennedy (JFK) Medical Center

Monrovia, Liberia

Redemption Hospital

Monrovia, Liberia

Duport Road Clinic

Paynesville, Liberia

MeSH Terms

Conditions

TuberculosisAcquired Immunodeficiency SyndromeSexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Mycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsHIV InfectionsBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsRetroviridae Infections

Study Officials

Stephen A Migueles, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
PRINCIPAL INVESTIGATOR

Enrollment

1,377 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: NIH
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 6, 2018

First Posted

November 7, 2018

Study Start

August 22, 2019

Actual (reported)

PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (1)

1

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (1)

1

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations